首页> 美国卫生研究院文献>Chemical Science >Photosensitizer synergistic effects: D–A–D structured organic molecule with enhanced fluorescence and singlet oxygen quantum yield for photodynamic therapy
【2h】

Photosensitizer synergistic effects: D–A–D structured organic molecule with enhanced fluorescence and singlet oxygen quantum yield for photodynamic therapy

机译:光敏剂的协同作用:D–A–D结构有机分子具有增强的荧光和单重态氧量子产率可用于光动力治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The development of photosensitizers with high fluorescence intensity and singlet oxygen (1O2) quantum yields (QYs) is of great importance for cancer diagnosis and photodynamic therapy (PDT). Diketopyrrolopyrrole (DPP) and boron dipyrromethene (BODIPY) are two kinds of building block with great potential for PDT. Herein, a novel donor–acceptor–donor (D–A–D) structured organic photosensitizer DPPBDPI with a benzene ring as a π bridge linking DPP and BODIPY has been designed and synthesized. The results indicate that the combination of DPP with BODIPY can simultaneously increase the fluorescence QY (5.0%) and the 1O2 QY (up to 80%) significantly by the synergistic effect of the two photosensitizers. By nanoprecipitation, DPPBDPI can form uniform nanoparticles (NPs) with a diameter of less than 100 nm. The obtained NPs not only exhibit high photo-toxicity, but also present negligible dark toxicity towards HeLa cells, demonstrating their excellent photodynamic therapeutic efficacy. In vivo fluorescence imaging shows that DPPBDPI NPs can target the tumor site quickly with the enhanced permeability and retention (EPR) effect and can effectively inhibit tumor growth using photodynamic therapy even with low doses (0.5 mg kg–1). The enhanced imaging and photodynamic performance of DPPBDPI suggest that the synergistic effect of DPP and BODIPY provides a novel theranostic platform for cancer diagnosis and photodynamic therapy.
机译:具有高荧光强度和单线态氧( 1 O2)量子产率(QYs)的光敏剂的开发对于癌症诊断和光动力疗法(PDT)至关重要。二酮基吡咯并吡咯(DPP)和硼二吡咯亚甲基(BODIPY)是两种具有PDT潜力的构件。本文设计并合成了一种新型的供体-受体-供体(D–A–D)结构的有机光敏剂DPPBDPI,其中苯环为连接DPP和BODIPY的π桥。结果表明,DPP与BODIPY的组合可以通过两种光敏剂的协同作用同时显着提高荧光QY(5.0%)和 1 O2 QY(最高80%)。通过纳米沉淀,DPPBDPI可以形成直径小于100 nm的均匀纳米颗粒(NP)。所获得的NP不仅表现出高的光毒性,而且对HeLa细胞的暗毒性可忽略不计,证明了其优异的光动力治疗功效。体内荧光成像显示,DPPBDPI NPs可以快速靶向肿瘤部位,并具有增强的通透性和保留(EPR)效果,并且即使在低剂量(0.5 mg kg –1 )下也可以通过光动力疗法有效抑制肿瘤生长)。 DPPBDPI的增强的成像和光动力性能表明,DPP和BODIPY的协同作用为癌症诊断和光动力治疗提供了一个新颖的治疗学平台。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号